317 related articles for article (PubMed ID: 37457287)
1. Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms.
Bekendam RH; Ravid K
Front Cell Dev Biol; 2023; 11():1207395. PubMed ID: 37457287
[TBL] [Abstract][Full Text] [Related]
2. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.
Marin Oyarzún CP; Heller PG
Front Immunol; 2019; 10():1373. PubMed ID: 31258539
[TBL] [Abstract][Full Text] [Related]
3. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
4. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
Barbui T; Falanga A
Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in
Wang Y; Ran F; Lin J; Zhang J; Ma D
Technol Cancer Res Treat; 2023; 22():15330338231154092. PubMed ID: 36744404
[TBL] [Abstract][Full Text] [Related]
6. Platelet function studies in myeloproliferative neoplasms patients with
Guy A; Helzy K; Mansier O; Bordet JC; Rivière E; Fiore M; James C
Res Pract Thromb Haemost; 2023 Feb; 7(2):100060. PubMed ID: 36908768
[TBL] [Abstract][Full Text] [Related]
7. ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms.
Castelli R; Berzuini A; Manetti R; Delitala AP; Castro D; Sanna G; Sircana MC; Profili NI; Bartoli A; La Cava L; Lambertenghi Deliliers G; Donadoni M; Gidaro A
Life (Basel); 2024 Apr; 14(4):. PubMed ID: 38672756
[TBL] [Abstract][Full Text] [Related]
8. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J; Zhou A; Oh ST
Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
10. Targets in MPNs and potential therapeutics.
Levy G; Mambet C; Pecquet C; Bailly S; Havelange V; Diaconu CC; Constantinescu SN
Int Rev Cell Mol Biol; 2022; 366():41-81. PubMed ID: 35153006
[TBL] [Abstract][Full Text] [Related]
11. Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia.
Marín Oyarzún CP; Glembotsky AC; Goette NP; Lev PR; De Luca G; Baroni Pietto MC; Moiraghi B; Castro Ríos MA; Vicente A; Marta RF; Schattner M; Heller PG
Front Immunol; 2020; 11():705. PubMed ID: 32425934
[TBL] [Abstract][Full Text] [Related]
12. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
14. Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Vianello F; Battisti A; Cella G; Marchetti M; Falanga A
ScientificWorldJournal; 2011 May; 11():1131-7. PubMed ID: 21623459
[TBL] [Abstract][Full Text] [Related]
15. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
Kaushansky K; Zhan H
Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
[TBL] [Abstract][Full Text] [Related]
16. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
17. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
18. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
19. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
Vannucchi AM
Intern Emerg Med; 2010 Jun; 5(3):177-84. PubMed ID: 19789961
[TBL] [Abstract][Full Text] [Related]
20. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
